Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Best Research Peptides for Stubborn Belly Fat: Mechanism Comparison

CJC-1295 (with DAC) GHRH analog. Extends endogenous GH half-life from 7 minutes to 6–8 days, amplifies pulse amplitude Pituitary GHRH receptors 1–2mg weekly (subcutaneous) 4–6 weeks for visceral adipose reduction measurable via imaging Most studied GH secretag

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • CJC-1295 (with DAC)
  • GHRH analog. Extends endogenous GH half-life from 7 minutes to 6–8 days, amplifies pulse amplitude
  • Pituitary GHRH receptors
  • 1–2mg weekly (subcutaneous)
  • 4–6 weeks for visceral adipose reduction measurable via imaging
  • Most studied GH secretagogue for sustained lipolytic effect without receptor downregulation. Ideal for protocols requiring maintained GH elevation
  • Tesamorelin
  • GHRH analog. FDA-approved for lipodystrophy, selectively reduces visceral fat without affecting subcutaneous deposits
  • 1–2mg daily (subcutaneous)
  • 8–12 weeks for CT-measurable visceral adipose area reduction
  • Clinical validation strongest of all research peptides. 15.2% visceral fat reduction demonstrated in Phase 3 trials; daily dosing required
  • AOD-9604
  • Modified hGH fragment (aa 177–191). Direct lipolytic action without IGF-1 elevation or insulin interference
  • Adipocyte beta-3 adrenergic receptors
  • 250–500mcg daily (subcutaneous)
  • 3–4 weeks for measurable fat mass reduction in research settings
  • Mechanistically elegant. Isolates GH's fat-burning effect from growth and metabolic side effects; shorter half-life requires daily administration
  • MOTS-c
  • Mitochondrial-derived peptide. Nuclear translocation triggers AMPK activation and metabolic gene expression
  • AMPK pathway / nuclear receptors
  • 5–10mg 2–3x weekly (subcutaneous or intranasal)
  • 2–3 weeks for improved fatty acid oxidation capacity
  • Indirect mechanism. Doesn't trigger lipolysis but dramatically increases muscle oxidative capacity; prevents visceral fat re-accumulation
  • GHRP-2
  • Growth hormone-releasing peptide. Direct GH secretagogue with ghrelin mimetic activity
  • Pituitary GHS-R1a receptors
  • 100–300mcg 1–3x daily (subcutaneous)
  • 2–4 weeks for GH-mediated lipolysis initiation
  • Shorter-acting than CJC-1295; often stacked with GHRH analogs for synergistic pulsatile GH release. Requires more frequent dosing

Related resources

More comparisons